Omnicell (NASDAQ:OMCL) EVP Sells 3,090 Shares of Stock

Omnicell, Inc. (NASDAQ:OMCL) EVP Nnamdi Njoku sold 3,090 shares of the stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $43.22, for a total value of $133,549.80. Following the completion of the transaction, the executive vice president directly owned 154,785 shares in the company, valued at $6,689,807.70. This represents a 1.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Omnicell Stock Performance

Shares of NASDAQ:OMCL traded up $0.60 during trading on Tuesday, hitting $43.82. The stock had a trading volume of 454,547 shares, compared to its average volume of 625,723. The company has a quick ratio of 1.29, a current ratio of 1.50 and a debt-to-equity ratio of 0.13. Omnicell, Inc. has a 12-month low of $26.84 and a 12-month high of $55.00. The stock has a market capitalization of $1.99 billion, a price-to-earnings ratio of 99.59, a price-to-earnings-growth ratio of 1.12 and a beta of 0.96. The stock has a 50-day simple moving average of $37.71 and a two-hundred day simple moving average of $40.60.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings results on Tuesday, April 28th. The company reported $0.55 earnings per share for the quarter, topping the consensus estimate of $0.33 by $0.22. Omnicell had a net margin of 1.67% and a return on equity of 4.00%. The company had revenue of $309.88 million for the quarter, compared to the consensus estimate of $304.02 million. During the same quarter in the prior year, the company earned $0.26 EPS. Omnicell’s quarterly revenue was up 14.9% on a year-over-year basis. Omnicell has set its FY 2026 guidance at 1.800-2.000 EPS and its Q2 2026 guidance at 0.400-48.000 EPS. On average, equities research analysts expect that Omnicell, Inc. will post 1.31 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Assenagon Asset Management S.A. lifted its position in Omnicell by 83.6% during the fourth quarter. Assenagon Asset Management S.A. now owns 258,231 shares of the company’s stock worth $11,698,000 after buying an additional 117,556 shares in the last quarter. Peregrine Capital Management LLC purchased a new position in Omnicell during the fourth quarter worth approximately $4,804,000. Dynamic Technology Lab Private Ltd lifted its position in Omnicell by 345.9% during the third quarter. Dynamic Technology Lab Private Ltd now owns 31,890 shares of the company’s stock worth $971,000 after buying an additional 24,738 shares in the last quarter. Dana Investment Advisors Inc. purchased a new position in Omnicell during the fourth quarter worth approximately $3,445,000. Finally, AlphaQuest LLC lifted its position in Omnicell by 388.4% during the third quarter. AlphaQuest LLC now owns 24,231 shares of the company’s stock worth $738,000 after buying an additional 19,270 shares in the last quarter. 97.70% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on OMCL shares. Bank of America upgraded shares of Omnicell from a “neutral” rating to a “buy” rating and set a $70.00 target price for the company in a research report on Wednesday, February 4th. Piper Sandler reaffirmed an “overweight” rating and set a $49.00 price target (down from $63.00) on shares of Omnicell in a research report on Friday, February 6th. Benchmark reaffirmed a “buy” rating on shares of Omnicell in a research report on Friday, March 13th. Zacks Research raised Omnicell from a “hold” rating to a “strong-buy” rating in a research report on Friday, May 1st. Finally, KeyCorp raised their target price on Omnicell from $60.00 to $70.00 and gave the stock an “overweight” rating in a report on Tuesday, April 28th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, Omnicell presently has an average rating of “Buy” and a consensus target price of $59.86.

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.